Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Brukinsa is a prescription kinase inhibitor containing zanubrutinib. It is approved for several B-cell malignancies in adults, including mantle cell lymphoma, Waldenstr?m macroglobulinemia, marginal zone lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and follicular lymphoma under specified treatment criteria. Brukinsa comes as 80 mg capsules and 160 mg tablets.
read more about brukinsa ...Zanubrutinib is a small-molecule inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the BTK active site, inhibiting BTK activity. BTK participates in B-cell receptor and cytokine receptor signaling involved in B-cell proliferation, trafficking, chemotaxis, and adhesion.
Brukinsa treats adults with mantle cell lymphoma after at least one prior therapy, Waldenstr?m macroglobulinemia, relapsed or refractory marginal zone lymphoma after an anti-CD20 regimen, and chronic lymphocytic leukemia or small lymphocytic lymphoma. It is also paired with obinutuzumab for relapsed or refractory follicular lymphoma after at least two systemic therapy lines.
The recommended Brukinsa dose is 160 mg twice daily or 320 mg once daily, taken with or without food until disease progression or unacceptable toxicity. Capsules are swallowed whole. Tablets are swallowed whole or split in half when prescribed and should not be chewed or crushed. Severe liver impairment and certain drug interactions require dose changes.
Serious risks include hemorrhage, infections, low blood cell counts, second cancers, cardiac arrhythmias, liver toxicity including drug-induced liver injury, and fetal harm. Blood counts and liver tests are checked during treatment. Strong or moderate CYP3A inhibitors or inducers can alter zanubrutinib exposure and require treatment or dose changes.
Yes. Zanubrutinib inhibits Bruton tyrosine kinase, a signaling protein involved in B-cell growth and survival pathways.
The recommended regimen is 160 mg twice daily or 320 mg once daily, with or without food.
Yes. Current labeling states that the 160 mg tablets can be split in half when prescribed.
Yes. Blood counts and liver tests are checked during treatment due risks of cytopenias and liver injury.
BRUKINSA (zanubrutinib) Prescribing Information. https://brukinsa.com/wp-content/uploads/brukinsa-prescribing-information.pdf. Date Accessed September 17, 2026.
DailyMed - BRUKINSA (zanubrutinib) capsule and tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902. Date Accessed September 17, 2026.
Definition of Zanubrutinib. National Cancer Institute Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zanubrutinib. Date Accessed September 17, 2026.
Zanubrutinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620009.html. Date Accessed September 17, 2026.
Zanubrutinib. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/zanubrutinib. Date Accessed September 17, 2026.